Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Gynecol Oncol. 2020 Jul 6;158(3):702–709. doi: 10.1016/j.ygyno.2020.06.481

Figure 1: Overall survival stratified by years of menopausal hormone therapy use.

Figure 1:

Adjusted survival curves among all women with ovarian cancer (n=6,419) and among women with advanced stage, high-grade serous cancer (n=4,393). The adjusted survival curves are generated from the hazard ratios estimated from a cox proportional hazards model of menopausal hormone therapy use and are adjusted for age at diagnosis, race/ethnicity, histotype (left panel only), stage at diagnosis, and OCAC site.